NWRN.SW - Newron Pharmaceuticals S.p.A.

Swiss - Swiss Delayed Price. Currency in CHF
7.48
-0.02 (-0.27%)
At close: 5:31PM CET
Stock chart is not supported by your current browser
Previous Close7.50
Open7.40
Bid7.00 x 0
Ask7.58 x 0
Day's Range7.26 - 7.62
52 Week Range5.33 - 13.78
Volume14,572
Avg. Volume31,073
Market Cap133.483M
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.35
  • Business Wire2 days ago

    Newron Pharmaceuticals: Commercialization Partner Zambon Together with Valeo Pharma Announce the Approval of Onstryv® (safinamide) for Parkinson’s Disease in Canada

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to note that its partner Zambon S.p.A, together with Valeo Pharma Inc., have announced the approval of Onstryv® (safinamide) for the treatment of Parkinson’s disease in Canada.

  • Business Wire2 months ago

    Zambon Announces Approval and ARTG Listing of Safinamide in Australia for Treatment of Patients with Parkinson’s Disease

    Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the recent approval of Xadago®/safinamide in Australia by the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the treatment of adult patients with fluctuating idiopathic Parkinson’s disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa). Under a partnership agreement with Zambon, Seqirus, a global leader in influenza prevention and a leading provider of essential vaccines and pharmaceuticals in Australia and New Zealand, has undertaken the registration with the Australian authorities and will now work to supply Xadago.

  • Business Wire3 months ago

    Newron Pharmaceuticals Hosts its 2018 R&D Day in New York City

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, welcomed investors, analysts and media today to its well-attended research and development (R&D) day in New York City, featuring leading medical experts presenting on schizophrenia, treatment resistant schizophrenia and Rett syndrome.

  • Business Wire3 months ago

    Investment Plan for Europe: EIB Backs Italian CNS Drug Developer Newron Pharmaceuticals with up to EUR 40m

    The European Investment Bank (EIB) and Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), signed a financing agreement today, which will allow the Company to borrow up to EUR 40 million over the coming years, subject to achieving a set of agreed performance criteria. This EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe, the Juncker Plan. “Neurological disorders affect up to one billion people worldwide1.

  • Business Wire3 months ago

    Newron Pharmaceuticals to Webcast Presentations from 2018 R&D Day Event on October 31

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, will webcast the presentations from its 2018 Research and Development Day in New York City on Wednesday, October 31, 2018 beginning at 10:00 AM EDT. Media and investors may access the live video webcast directly at https://livestream.com/Convene/Newron2018 beginning at 10:00 AM EDT. This research and investor update event will feature presentations from Newron’s senior executive management team as well as two of the leading clinicians in the fields of schizophrenia and Rett syndrome, John Kane, MD, Professor and Chairman of the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Daniel Glaze, MD, Neurologist and Professor at Baylor College of Medicine in Houston, Texas.

  • Business Wire3 months ago

    Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, will host a research and development day featuring leading medical experts presenting on schizophrenia, treatment resistant schizophrenia and Rett syndrome on Wednesday, October 31, 2018 in New York City.

  • Business Wire3 months ago

    Newron Dedicates Efforts to Research and Advocacy During Rett Awareness Month in October

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, is pleased to support Rett Syndrome Awareness Month 2018. Ahead of the month, Newron participated at the international conference, “Rett Syndrome Research, Towards the Future” in Rome on September 27-29, 2018. This conference brought together the latest findings from researchers internationally, and importantly, involved the perspective of caregivers of Rett syndrome patients, who discussed how caregivers are also impacted by the disease.

  • Business Wire4 months ago

    Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY, on Wednesday, October 3 at 3:25 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire4 months ago

    Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City – Save the Date

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that its 2018 R&D Day will be held in New York City on October 31, 2018, from 10:00AM to 1:00PM EDT. Stefan Weber, Chief Executive Officer, Ravi Anand, CMO, and other senior members of Newron’s management team will host the event, which will focus on the Company’s clinical and commercial pipeline, regulatory updates and financial outlook.

  • Business Wire5 months ago

    Newron Pharmaceuticals to Present at H.C. Wainwright Annual Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the H.C. Wainwright Annual Healthcare Conference in New York, NY, on Wednesday, September 05, 2018 at 5:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire6 months ago

    Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the Wedbush PacGrow Healthcare Conference in New York, NY, on Wednesday, August 15, 2018 at 1:20 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire7 months ago

    Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces that the STARS clinical study (Sarizotan Treatment of Apneas in Rett Syndrome) in patients with Rett syndrome is expected to complete enrollment in H2 2018. Newron expects to report results from the STARS study in H1 2019. Based on the current rate of screening and qualification, Newron anticipates that randomization of the target number of 129 patients will be completed in H2 2018.

  • Business Wire8 months ago

    Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the Jefferies 2018 Healthcare Conference in New York, NY on Tuesday, June 5, 2018 at 4:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire8 months ago

    Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 2018

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the UBS Global Healthcare Conference 2018 in New York, NY on Tuesday, May 22, 2018 at 3:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire10 months ago

    Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that shareholders either unanimously or with vast majorities approved all motions on the agenda of its shareholders’ annual meeting held in Bresso , Italy, today.

  • Business Wire11 months ago

    Newron Announces 2017 Financial Results and Provides Outlook for 2018

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces its financial results and operational highlights for the year ended December 31, 2017, and provides an outlook for 2018.

  • Business Wire11 months ago

    Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its support of this year’s Rare Disease Day®.

  • Business Wire11 months ago

    Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.

  • Business Wire11 months ago

    Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 20th Annual BIO CEO & Investor Conference in New York, NY on Monday, Feb.